Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
$0.40
+1.3%
$0.39
$0.30
$10.62
$56.63M1.822.96 million shs1.98 million shs
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
$0.65
-0.4%
$0.94
$0.43
$11.18
$10.38M3.36935,500 shs2.50 million shs
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
$1.31
-0.5%
$1.46
$0.85
$4.42
$60.11M1.21473,336 shs824,363 shs
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
$3.89
-7.8%
$2.70
$1.14
$7.47
$120.36M1.95504,541 shs1.01 million shs
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
+7.05%+16.76%0.00%+24.64%-92.12%
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
+0.91%+37.14%-44.58%-31.20%-74.05%
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
+3.94%+3.94%-22.81%+37.03%-60.83%
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
-2.99%+1.20%+79.80%+213.99%-24.37%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
3.7793 of 5 stars
3.31.00.04.70.61.71.3
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
3.3861 of 5 stars
3.65.00.00.02.21.70.6
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
1.9379 of 5 stars
3.74.00.00.00.90.00.0
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
2.2676 of 5 stars
3.54.00.00.02.50.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
2.50
Moderate Buy$6.101,425.00% Upside
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
3.29
Buy$11.101,603.50% Upside
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
3.33
Buy$9.00584.93% Upside
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
3.00
Buy$16.60326.74% Upside

Current Analyst Ratings Breakdown

Latest GOVX, SKYE, PDSB, and APLT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/1/2025
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$13.00
6/24/2025
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$15.00
6/16/2025
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00
6/11/2025
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$13.00
5/20/2025
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
5/14/2025
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Perform ➝ Sector Perform$1.50 ➝ $1.50
5/2/2025
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$14.00 ➝ $9.00
4/16/2025
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
4/15/2025
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
Alliance Global Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $8.50
4/10/2025
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$18.00 ➝ $18.00
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
$460K123.11N/AN/A$0.49 per share0.82
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
$5.59M1.86N/AN/A$0.48 per share1.36
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
N/AN/AN/AN/A$0.51 per shareN/A
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
N/AN/AN/AN/A$2.25 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
-$105.62M-$0.43N/AN/AN/AN/A-184.67%-84.02%8/6/2025 (Estimated)
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
-$24.99M-$3.65N/AN/AN/A-438.20%-511.96%-286.58%8/5/2025 (Estimated)
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
-$37.61M-$0.94N/AN/AN/AN/A-150.59%-69.15%8/12/2025 (Estimated)
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
-$26.57M-$0.82N/AN/AN/AN/A-53.92%-48.58%N/A

Latest GOVX, SKYE, PDSB, and APLT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
-$0.17N/AN/AN/A$0.42 millionN/A
8/5/2025Q2 2025
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
-$0.41N/AN/AN/A$0.37 millionN/A
5/14/2025Q1 2025
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
-$0.25-$0.21+$0.04-$0.21N/AN/A
5/8/2025Q1 2025
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
-$0.31-$0.28+$0.03-$0.28N/AN/A
5/1/2025Q1 2025
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
-$0.59-$0.45+$0.14-$0.45$0.75 million$1.64 million
4/14/2025Q4 2024
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
-$0.18-$0.24-$0.06$0.33$0.61 million$0.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
N/AN/AN/AN/AN/A
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
N/AN/AN/AN/AN/A
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
N/AN/AN/AN/AN/A
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
N/A
3.00
3.00
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
N/A
3.62
3.62
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
0.29
2.33
2.33
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
N/A
11.85
11.85

Institutional Ownership

CompanyInstitutional Ownership
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
98.31%
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
6.09%
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
26.84%
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
21.09%

Insider Ownership

CompanyInsider Ownership
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
1.60%
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
1.20%
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
9.20%
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
4.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
30141.58 million139.31 millionOptionable
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
1015.93 million15.73 millionNot Optionable
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
2045.71 million41.51 millionOptionable
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
1130.98 million29.58 millionOptionable

Recent News About These Companies

Skye Bioscience, Inc. (SKYE) - Yahoo Finance

New MarketBeat Followers Over Time

Media Sentiment Over Time

Applied Therapeutics stock logo

Applied Therapeutics NASDAQ:APLT

$0.40 +0.01 (+1.27%)
As of 03:26 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

GeoVax Labs stock logo

GeoVax Labs NASDAQ:GOVX

$0.65 0.00 (-0.35%)
As of 03:10 PM Eastern

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.

PDS Biotechnology stock logo

PDS Biotechnology NASDAQ:PDSB

$1.31 -0.01 (-0.45%)
As of 03:25 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.

Skye Bioscience stock logo

Skye Bioscience NASDAQ:SKYE

$3.89 -0.33 (-7.82%)
As of 03:26 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.